Key takeaways
- New GLP-1 medicine are coming onto the market in 2026 and past
- These new merchandise might widen up GLP-1 medicine to a a lot bigger and completely different viewers: creating an excellent greater affect on F&B than seen to this point and shifting who core customers are
- New medicine might even have completely different impacts on how individuals react to food and drinks: and due to this fact what they need and wish from merchandise.
An unimaginable one in 10 American adults are already taking GLP-1 medicine. Merchandise like Wegovy, Ozempic, Zepbound and Mounjaro at the moment are family names.
And that quantity might simply proceed to rise as extra medicine come onto the market. And the subsequent era of medicine received’t be GLP-1 medicine as we all know them: they’ll be cheaper, extra accessible, more practical and with fewer unwanted effects.
Food and drinks firms are innovating round GLP-1 customers. They’re desirous about how merchandise can meet the wants of GLP-1 customers: with merchandise for protein or hydration. However the wants of GLP-1 customers might evolve considerably as new medicine come onto the market.
So what are the medicine coming by way of the pipeline?
New launch: Orforglipron
Simply accepted: Eli Lilly’s Foundayo (orforglipron).
This drug, which acquired the inexperienced gentle from the FDA on April 1, stands out as a result of it’s a pill: an enormous attraction for the tens of millions of people that battle with needles and injections.
Denmark’s Novo Nordisk had already received the race to get an oral GLP-1 drug onto the market (with a model of Wegovy in December): however Eli Lilly’s drug might shake up the market. The corporate will provide the tablet by way of its personal platform LillyDirect, which is already accepting prescriptions and with prices beginning at $25 per thirty days with business protection (or $149 with self-pay).
Whereas many observers are fixated on which is best, the fact is that having two varieties of drugs available on the market will propel the general GLP-1 market onto a brand new degree.
To start with, drugs can attain a a lot wider inhabitants: aside from addressing the needle phobia held by many sufferers, drugs are typically simpler to make and distribute than injectable medicine. And with two varieties of medicine available on the market, anticipate competitors on pricing.
‘GLP-3’s: Retatrutide
Prepare for ‘GLP-3s’.
Retatrutide is a ‘triple agonist’ from Eli Lilly concurrently prompts three receptors: GLP-1, GIP and glucagon. By focusing on three pathways, it suppresses urge for food, improves glucose management and boosts calorie burning extra successfully than present easy or twin agonists.
American pharmaceutical big, Eli Lilly, has already demonstrated the security and superior efficacy of the drug in late-stage scientific trials. However these trials are nonetheless ongoing. Full information is predicted in mid-2026: which might put an FDA resolution on the drug into late 2027 or 2028.
(It’s value noting that the time period GLP-3 shouldn’t be scientifically correct: however has emerged in mainstream media as a strategy to describe the triple pathways of the drug).
Understanding GLP-1 drug improvement: pharmaceutical cheat sheet
Investigational medicine: These not but accepted by regulatory approvals and never obtainable for public use
Scientific trials: Human trials to show the security and efficacy of an investigational drug (or an present drug for a brand new use): typically compared to its opponents.
Part 3 trials: Massive scale scientific trials with information used to tell regulatory functions
FDA approval: All new medicine within the US want the inexperienced gentle from the US Meals and Drug Administration. In Europe, they want the inexperienced gentle from the European Medicines Company (EMA). Within the UK, the MHRA controls drug laws.
Triple power: Excessive dose Wegovy
A normal dose of Wegovy is 2.4mg: the newly accepted excessive dose shot is an unimaginable thrice as robust at 7.2mg.
This tremendous shot was accepted by the FDA final month to be used in individuals who tolerate the two.4mg dose for a minimum of 4 weeks: with a scientific trial suggesting it may possibly assist sufferers obtain 25% weight reduction and even greater.
Greater is best: the next dose ought to imply faster, extra substantial weight reduction within the individuals who want it probably the most.
Double energy: CagriSema
Novo Nordisk’s CagriSema builds on the success of semaglutide by combining it with an amylin analogue (amylin helps handle blood sugar).
Outcomes haven’t been as robust as Novo Nordisk had hoped for (the drug didn’t beat Eli Lilly’s Zepbound in scientific trial outcomes introduced in February, sending the corporate’s share worth spiralling down in response).
However CagriSema nonetheless exhibits superior weight reduction to semaglutide alone. And its essential to do not forget that many individuals on present GLP-1 medicine don’t truly see any advantages (almost 1 / 4, based on some estimates), so twin and triple medicine (like retatrutide above) with extra pathways for weight reduction might show to be essential in reaching these audiences.
An utility for medical approval is already with US authorities, and a choice is predicted within the second half of 2026. That may imply a 2027 launch.
MariTide
Most GLP-1 medicine require day by day or weekly injections, relying on the precise treatment required.
Amgen’s maridebart cafraglutide (MariTide for brief), nonetheless, can be injected simply month-to-month: or probably even much less.
MariTide is in Part 3 trials, though outcomes should not anticipated till 2027 which might put commercialisation behind among the different GLP-1 contenders within the pipeline.
What do meals and beverage producers have to know?
So what do these new contenders imply for meals and beverage?
The primary is solely the size of GLP-1 medicine and their affect. Extra medicine available on the market imply extra competitors, and extra competitors means decrease costs: which means that they turn out to be inside attain of extra individuals.
In markets such because the US, the query of well being protection additionally turns into a essential issue. From July 1, 2026, Medicare will cowl Wegovy and Zepbound for weight reduction by way of a short lived federal program referred to as the Medicare GLP-1 bridge: with a brand new mannequin coming into place in 2027. That may once more open up the GLP-1 market to much more individuals.
Then there’s additionally the query of efficacy. Not each GLP-1 drug works in the identical method for each affected person: and never each affected person sees the load loss they had been hoping for. New medicine, with completely different mechanisms, might once more widen up the viewers.
In flip, meaning extra individuals will likely be on the lookout for meals and beverage merchandise that meet their weight reduction wants.
For meals and drinks manufacturers seeking to innovate and embrace the wants of GLP-1 customers, it’s going to be about taking a look at the place the longer term customers are coming from.
“The most important alternative segments might not even be probably the most distinguished customers immediately,” stated John Dick, CEO and founding father of shopper behaviour consultancy CivicScience.
“As prices of GLP1s come down, and insurance coverage firms extra often cowl them, an enormous new phase of non-coastal, middle-income, and rural Individuals – the place weight problems charges are highest – will enter the market in droves.
“The wants, habits, and model preferences of those new customers will range broadly from the everyday GLP-1 person immediately.”
After which there’s the query of how GLP-1 customers react to food and drinks. Proper now, producers are studying how you can adapt to GLP-1 customers: offering packaged meals that align with new dietary wants, altering appetites and altered consuming behaviour.
Whereas the basics are more likely to stay the identical (all GLP-1 medicine, for instance, work by suppressing urge for food, which means smaller parts are important), how individuals react to newer medicine might throw up loads of surprises. Even the unwanted effects of recent medicine might reshape what customers do – and don’t – need from their food and drinks.
And even the smallest shift in how individuals react to such medicine (whether or not that’s by way of ingesting much less alcohol, needing extra hydration, or muting ‘meals noise’) might have a huge effect on what individuals need from meals and drinks.
Drug improvement is pricey: and the brand new medicine within the pipeline are solely there as a result of they maintain the potential to for mass market success. Which means the GLP-1 contenders might make the panorama very completely different in simply a few years.
Meals and beverage producers, due to this fact, should pay shut consideration to the most recent medicine coming by way of the pipeline and anticipate what merchandise will likely be wanted to satisfy customers’ wants.
